JP2989002B2
(ja)
*
|
1988-12-22 |
1999-12-13 |
キリン―アムジエン・インコーポレーテツド |
化学修飾顆粒球コロニー刺激因子
|
DK0393438T3
(da)
|
1989-04-21 |
2005-05-30 |
Amgen Inc |
TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
|
US7264944B1
(en)
|
1989-04-21 |
2007-09-04 |
Amgen Inc. |
TNF receptors, TNF binding proteins and DNAs coding for them
|
IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
US6143866A
(en)
*
|
1989-07-18 |
2000-11-07 |
Amgen, Inc. |
Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
|
US6552170B1
(en)
*
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
US5595732A
(en)
*
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
US5880131A
(en)
*
|
1993-10-20 |
1999-03-09 |
Enzon, Inc. |
High molecular weight polymer-based prodrugs
|
US5919455A
(en)
*
|
1993-10-27 |
1999-07-06 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
US5951974A
(en)
*
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
PT730470E
(pt)
*
|
1993-11-10 |
2002-08-30 |
Enzon Inc |
Conjugados melhorados de interferao-polimero
|
AU1916295A
(en)
*
|
1994-02-08 |
1995-08-29 |
Amgen, Inc. |
Oral delivery of chemically modified proteins
|
US5730990A
(en)
*
|
1994-06-24 |
1998-03-24 |
Enzon, Inc. |
Non-antigenic amine derived polymers and polymer conjugates
|
US20030053982A1
(en)
*
|
1994-09-26 |
2003-03-20 |
Kinstler Olaf B. |
N-terminally chemically modified protein compositions and methods
|
DE4435087A1
(de)
*
|
1994-09-30 |
1996-04-04 |
Deutsches Krebsforsch |
Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen
|
US5824784A
(en)
*
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
US5738846A
(en)
*
|
1994-11-10 |
1998-04-14 |
Enzon, Inc. |
Interferon polymer conjugates and process for preparing the same
|
JP2758154B2
(ja)
*
|
1995-04-06 |
1998-05-28 |
エフ・ホフマン−ラ ロシユ アーゲー |
インターフェロンを含む液体製剤
|
DE19514087A1
(de)
*
|
1995-04-13 |
1996-10-17 |
Deutsches Krebsforsch |
Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein
|
US5908621A
(en)
*
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
DE69632062T2
(de)
|
1995-11-02 |
2004-11-18 |
Schering Corp. |
Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
|
TW517067B
(en)
*
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
TW555765B
(en)
*
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
US7495087B2
(en)
|
1997-07-14 |
2009-02-24 |
Bolder Biotechnology, Inc. |
Cysteine muteins in the C-D loop of human interleukin-11
|
US20080076706A1
(en)
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
CA2296770A1
(en)
*
|
1997-07-14 |
1999-01-28 |
Bolder Biotechnology, Inc. |
Derivatives of growth hormone and related proteins
|
US7270809B2
(en)
*
|
1997-07-14 |
2007-09-18 |
Bolder Biotechnology, Inc. |
Cysteine variants of alpha interferon-2
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
CN1276730A
(zh)
*
|
1997-09-18 |
2000-12-13 |
霍夫曼-拉罗奇有限公司 |
α-干扰素和金刚胺用于治疗慢性丙型肝炎的应用
|
JP4465109B2
(ja)
|
1997-12-17 |
2010-05-19 |
エンゾン ファーマシューティカルズ,インコーポレーテッド |
アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ
|
US6180095B1
(en)
*
|
1997-12-17 |
2001-01-30 |
Enzon, Inc. |
Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
|
US5985263A
(en)
*
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
US5981709A
(en)
*
|
1997-12-19 |
1999-11-09 |
Enzon, Inc. |
α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
|
FR2774687B1
(fr)
*
|
1998-02-06 |
2002-03-22 |
Inst Nat Sante Rech Med |
Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
|
CO5080738A1
(es)
*
|
1998-03-26 |
2001-09-25 |
Schering Corp |
Formulaciones para la proteccion de conjugados de peginter- feron alfa
|
US6180096B1
(en)
|
1998-03-26 |
2001-01-30 |
Schering Corporation |
Formulations for protection of peg-interferon alpha conjugates
|
SK286654B6
(sk)
*
|
1998-04-28 |
2009-03-05 |
Laboratoires Serono Sa |
Spôsob postupného pripájania polyetylénglykolových častí a použitie PEG-polypeptidových konjugátov vyrobených týmto spôsobom
|
ES2172288T3
(es)
|
1998-05-15 |
2002-09-16 |
Schering Corp |
Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c.
|
US6372712B1
(en)
|
1998-05-22 |
2002-04-16 |
The Board Of Trustees Of The Leland Stanford Jr. University |
Synthetic bifunctional molecules containing a drug moiety and presenter protein ligand
|
ITMI981148A1
(it)
*
|
1998-05-22 |
1999-11-22 |
Therapicon Srl |
Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
|
PL192364B1
(pl)
*
|
1998-06-08 |
2006-10-31 |
Hoffmann La Roche |
Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną
|
US20030143662A1
(en)
*
|
1998-06-16 |
2003-07-31 |
Cummings Richard D. |
Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
|
US7223845B2
(en)
|
1998-06-16 |
2007-05-29 |
The Board Of Regents Of The University Of Oklahoma |
Synthetic glycosulfopeptides and methods of synthesis thereof
|
EP1087996B1
(en)
*
|
1998-06-16 |
2007-01-17 |
The Board of Regents of The University of Oklahoma |
Glycosulfopeptides and methods of synthesis and use thereof
|
MXPA01003790A
(es)
*
|
1998-10-16 |
2002-09-18 |
Biogen Inc |
Proteinas de fusion beta - interferon y sus usos.
|
ES2630278T3
(es)
*
|
1998-10-16 |
2017-08-21 |
Biogen Ma Inc. |
Conjugados poliméricos de interferón beta-1a y usos de los mismos
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
BR122013003013B8
(pt)
|
1999-01-14 |
2021-07-06 |
Bolder Biotechnology Inc |
proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
|
HU228488B1
(en)
*
|
1999-01-29 |
2013-03-28 |
Amgen Inc |
Gcsf conjugates
|
DE60020444T2
(de)
|
1999-04-08 |
2006-05-04 |
Schering Corp. |
Melanoma Therapie
|
US6605273B2
(en)
|
1999-04-08 |
2003-08-12 |
Schering Corporation |
Renal cell carcinoma treatment
|
US6362162B1
(en)
|
1999-04-08 |
2002-03-26 |
Schering Corporation |
CML Therapy
|
US6923966B2
(en)
|
1999-04-08 |
2005-08-02 |
Schering Corporation |
Melanoma therapy
|
JO2291B1
(en)
|
1999-07-02 |
2005-09-12 |
اف . هوفمان لاروش ايه جي |
Erythropoietin derivatives
|
JP4737903B2
(ja)
|
1999-07-07 |
2011-08-03 |
ザイモジェネティクス, インコーポレイテッド |
ヒトサイトカイン受容体
|
WO2001005819A1
(en)
*
|
1999-07-15 |
2001-01-25 |
Kuhnil Pharm. Co., Ltd. |
Novel water soluble-cyclosporine conjugated compounds
|
US7144574B2
(en)
*
|
1999-08-27 |
2006-12-05 |
Maxygen Aps |
Interferon β variants and conjugates
|
US7431921B2
(en)
*
|
2000-04-14 |
2008-10-07 |
Maxygen Aps |
Interferon beta-like molecules
|
US6531122B1
(en)
*
|
1999-08-27 |
2003-03-11 |
Maxygen Aps |
Interferon-β variants and conjugates
|
US6969524B1
(en)
|
1999-10-12 |
2005-11-29 |
Santen Pharamceutical Co., Ltd. |
Interferon complex and medicinal use thereof
|
CN1309423C
(zh)
|
1999-11-12 |
2007-04-11 |
马克西根控股公司 |
干扰素γ偶联物
|
KR20020065517A
(ko)
*
|
1999-11-12 |
2002-08-13 |
맥시겐 홀딩스 리미티드 |
인터페론 감마 접합체
|
US7220552B1
(en)
|
1999-11-19 |
2007-05-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Bifunctional molecules and their use in the disruption of protein-protein interactions
|
WO2001035978A1
(en)
|
1999-11-19 |
2001-05-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Targeted bifunctional molecules and therapies based thereon
|
US6887842B1
(en)
|
1999-11-19 |
2005-05-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
|
WO2001040467A1
(en)
|
1999-12-03 |
2001-06-07 |
Zymogenetics, Inc. |
Human cytokine receptor
|
BR0107561A
(pt)
|
2000-01-10 |
2002-11-19 |
Maxygen Holdings Ltd |
Polipeptìdios ou conjugados entre polipeptìdios que exibem atividade (g-csf), métodos de preparação dos mesmos e seus usos
|
EP1908477A3
(en)
*
|
2000-01-24 |
2008-06-11 |
Schering Corporation |
Combination of temozolomide and pegylated interferon-alpha for treating cancer
|
EP1251866A1
(en)
*
|
2000-01-24 |
2002-10-30 |
Schering Corporation |
Combination of temozolomide and pegylated interferon-alpha for treating cancer
|
EP1257295B1
(en)
|
2000-02-11 |
2009-04-15 |
Bayer HealthCare LLC |
Factor vii or viia-like molecules
|
KR100353392B1
(ko)
*
|
2000-03-13 |
2002-09-18 |
선바이오(주) |
높은 생체 활성도를 갖는 생체 활성 단백질과 peg의결합체 제조방법
|
US6777387B2
(en)
|
2000-03-31 |
2004-08-17 |
Enzon Pharmaceuticals, Inc. |
Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
|
US6756037B2
(en)
|
2000-03-31 |
2004-06-29 |
Enzon, Inc. |
Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
|
US20040082765A1
(en)
*
|
2000-10-16 |
2004-04-29 |
Teruo Nakamura |
Peg-modified erythropoietin
|
US20020169290A1
(en)
*
|
2000-11-02 |
2002-11-14 |
Claus Bornaes |
New multimeric interferon beta polypeptides
|
CA2428242A1
(en)
|
2000-11-07 |
2002-05-16 |
Zymogenetics, Inc. |
Human tumor necrosis factor receptor
|
AU2002238052A1
(en)
|
2001-02-20 |
2002-09-04 |
Zymogenetics, Inc. |
Antibodies that bind both bcma and taci
|
DE60223499T2
(de)
*
|
2001-02-20 |
2008-10-16 |
Enzon, Inc. |
Terminal verzweigte, polymere linker und diese enthaltende polymere konjugate
|
SK11882003A3
(sk)
|
2001-02-27 |
2004-03-02 |
Maxygen Aps |
Variant štandardného ľudského interferónu ß, nukleotidová sekvencia kódujúca tento variant, expresný vektor a hostiteľská bunka s jej obsahom, farmaceutický prostriedok s obsahom uvedeného variantu a jeho použitie
|
JP2004532624A
(ja)
|
2001-03-02 |
2004-10-28 |
ザイモジェネティクス,インコーポレイティド |
マウスサイトカイン受容体
|
US7038015B2
(en)
*
|
2001-04-06 |
2006-05-02 |
Maxygen Holdings, Ltd. |
Interferon gamma polypeptide variants
|
US6958388B2
(en)
|
2001-04-06 |
2005-10-25 |
Maxygen, Aps |
Interferon gamma polypeptide variants
|
WO2002083166A1
(fr)
*
|
2001-04-10 |
2002-10-24 |
Santen Pharmaceutical Co., Ltd. |
Complexes de polymeres d'interferons et leur utilisation medicinale
|
EA007275B1
(ru)
|
2001-05-24 |
2006-08-25 |
Займодженетикс, Инк. |
Слитые белки taci-иммуноглобулина
|
JP4142569B2
(ja)
*
|
2001-06-22 |
2008-09-03 |
協和醗酵工業株式会社 |
軟膏剤
|
MD2053C2
(ro)
*
|
2001-07-10 |
2003-07-31 |
Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова |
Remediu cu acţiune interferonogenă
|
US7125558B2
(en)
|
2001-08-22 |
2006-10-24 |
Bioartificial Gel Technologies Inc, |
Process for the preparation of activated polyethylene glycols
|
WO2003049760A1
(en)
*
|
2001-12-07 |
2003-06-19 |
Intermune, Inc. |
Compositions and method for treating hepatitis virus infection
|
KR100888371B1
(ko)
|
2002-01-17 |
2009-03-13 |
동아제약주식회사 |
가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제
|
JP2005526151A
(ja)
*
|
2002-01-18 |
2005-09-02 |
バイオゲン アイデック エムエー インク. |
生物学的に活性な化合物の結合のための部分を有するポリアルキレングリコール
|
AU2003221291A1
(en)
*
|
2002-03-13 |
2003-09-22 |
Beijing Jiankai Technology Co., Ltd. |
Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
|
WO2003087308A2
(en)
*
|
2002-04-11 |
2003-10-23 |
Zymogenetics, Inc. |
Use of interleukin-24 to treat ovarian cancer
|
JP4409962B2
(ja)
|
2002-04-19 |
2010-02-03 |
ザイモジェネティクス,インコーポレイティド |
サイトカイン受容体
|
AU2003240439B2
(en)
|
2002-06-21 |
2009-05-21 |
Novo Nordisk Health Care Ag |
Pegylated factor VII glycoforms
|
US7524931B2
(en)
*
|
2002-07-03 |
2009-04-28 |
Maxygen Holdings Ltd. |
Full-length interferon gamma polypeptide variants
|
WO2004012773A1
(en)
*
|
2002-07-24 |
2004-02-12 |
F. Hoffmann-La Roche Ag |
Polyalkylene glycol acid additives
|
WO2004021991A2
(en)
*
|
2002-09-05 |
2004-03-18 |
The General Hospital Corporation |
Asialo-interferons and the treatment of liver cancer
|
MXPA05002476A
(es)
*
|
2002-09-05 |
2005-10-19 |
Gi Company Inc |
Asialo-interferones modificados y sus usos.
|
DE60313786T2
(de)
*
|
2002-09-27 |
2008-01-24 |
F. Hoffmann-La Roche Ag |
Poly(ethylen glykol)-konjugate von insulinähnlichem wachstumfaktor bindenden protein-4
|
US20040175359A1
(en)
*
|
2002-11-12 |
2004-09-09 |
Desjarlais John Rudolph |
Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
|
US7314613B2
(en)
*
|
2002-11-18 |
2008-01-01 |
Maxygen, Inc. |
Interferon-alpha polypeptides and conjugates
|
PL219741B1
(pl)
*
|
2002-12-26 |
2015-07-31 |
Mountain View Pharmaceuticals |
Sposób zwiększania antyproliferacyjnego potencjału nieglikozylowanego interferonu-beta-1b in vitro, koniugat wytworzony tym sposobem i jego zastosowanie oraz kompozycja farmaceutyczna zawierająca koniugat i jej zastosowanie
|
PL380269A1
(pl)
*
|
2002-12-26 |
2007-01-08 |
Mountain View Pharmaceuticals, Inc. |
Koniugaty polimerowe cytokin, czynników wzrostu, hormonów polipeptydowych i ich antagonistów o zachowanej zdolności do wiązania receptora
|
CN1744918A
(zh)
*
|
2002-12-31 |
2006-03-08 |
尼克塔治疗亚拉巴马公司 |
含有酮或相关官能团的聚合物试剂
|
BRPI0407511A
(pt)
*
|
2003-02-19 |
2006-02-14 |
Pharmacia Corp |
ésteres de polietilenoglicol ativados
|
CN1997666A
(zh)
*
|
2003-02-26 |
2007-07-11 |
印特缪恩股份有限公司 |
聚乙二醇修饰的干扰素组合物及其使用方法
|
US20070077225A1
(en)
*
|
2003-02-28 |
2007-04-05 |
Blatt Lawrence M |
Continuous delivery methods for treating hepatitis virus infection
|
CA2458085A1
(en)
|
2003-03-21 |
2004-09-21 |
F. Hoffmann-La Roche Ag |
Transcriptional activity assay
|
US20070172446A1
(en)
|
2003-05-16 |
2007-07-26 |
Intermune, Inc. |
Synthetic chemokine receptor ligands and methods of use thereof
|
EP1668031B1
(en)
|
2003-08-07 |
2008-03-12 |
ZymoGenetics, Inc. |
Homogeneous preparations of il-29
|
GB0320638D0
(en)
|
2003-09-03 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
EP1673387B1
(en)
|
2003-10-10 |
2010-09-15 |
Novo Nordisk A/S |
Il-21 derivatives
|
AU2004281780B2
(en)
|
2003-10-14 |
2009-03-19 |
F. Hoffmann-La Roche Ltd |
Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
|
ES2428358T3
(es)
|
2003-10-17 |
2013-11-07 |
Novo Nordisk A/S |
Terapia de combinación
|
US20050089952A1
(en)
*
|
2003-10-22 |
2005-04-28 |
Akzo Nobel N.V. |
Apparatuses and processes for increasing protein PEGylation reaction yields
|
WO2005040758A2
(en)
*
|
2003-10-24 |
2005-05-06 |
Intermune, Inc. |
Use of pirfenidone in therapeutic regimens
|
WO2005062949A2
(en)
*
|
2003-12-23 |
2005-07-14 |
Intermune, Inc. |
Method for treating hepatitis virus infection
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
WO2005074524A2
(en)
*
|
2004-02-02 |
2005-08-18 |
Ambrx, Inc. |
Modified human interferon polypeptides and their uses
|
US7351787B2
(en)
*
|
2004-03-05 |
2008-04-01 |
Bioartificial Gel Technologies, Inc. |
Process for the preparation of activated polyethylene glycols
|
MXPA06013412A
(es)
*
|
2004-05-19 |
2007-01-23 |
Maxygen Inc |
Polipeptidos de interferon-alfa y conjugados.
|
US20060018875A1
(en)
*
|
2004-06-14 |
2006-01-26 |
Blatt Lawrence M |
Interferon compositions and methods of use thereof
|
US7632924B2
(en)
*
|
2004-06-18 |
2009-12-15 |
Ambrx, Inc. |
Antigen-binding polypeptides and their uses
|
CA2569381A1
(en)
*
|
2004-07-21 |
2006-08-31 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
CN101829318B
(zh)
|
2004-07-29 |
2012-07-04 |
津莫吉尼蒂克斯有限责任公司 |
Il-28和il-29治疗癌症和自身免疫性疾病的用途
|
KR20070045244A
(ko)
|
2004-08-12 |
2007-05-02 |
쉐링 코포레이션 |
안정한 페길화된 인터페론 제형
|
WO2006034455A2
(en)
|
2004-09-23 |
2006-03-30 |
Vasgene Therapeutics, Inc. |
Polipeptide compounds for inhibiting angiogenesis and tumor growth
|
US7736872B2
(en)
*
|
2004-12-22 |
2010-06-15 |
Ambrx, Inc. |
Compositions of aminoacyl-TRNA synthetase and uses thereof
|
CA2590462C
(en)
*
|
2004-12-22 |
2017-02-28 |
Ambrx, Inc. |
Methods for expression and purification of recombinant human growth hormone
|
BRPI0519170A8
(pt)
*
|
2004-12-22 |
2018-05-08 |
Ambrx Inc |
formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
|
EP2284191A3
(en)
|
2004-12-22 |
2011-07-20 |
Ambrx, Inc. |
Process for the preparation of hGH
|
US20060177447A1
(en)
|
2005-02-08 |
2006-08-10 |
Wenfeng Xu |
Anti-IL-20, anti-IL-22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
|
JP2008544746A
(ja)
|
2005-05-12 |
2008-12-11 |
ザイモジェネティクス, インコーポレイテッド |
免疫応答を調節するための組成物および方法
|
KR20080019619A
(ko)
*
|
2005-05-18 |
2008-03-04 |
맥시겐, 인크. |
개량된 인터페론-알파 폴리펩티드
|
CN101247821B
(zh)
*
|
2005-06-03 |
2013-01-23 |
Ambrx公司 |
经改良人类干扰素分子和其用途
|
MX2007015819A
(es)
*
|
2005-06-13 |
2008-02-22 |
Nastech Pharm Co |
Suministro de derivados peptidicos a traves de la mucosa.
|
CN101242842A
(zh)
|
2005-06-17 |
2008-08-13 |
诺瓦提斯公司 |
Sanglifehrin在hcv中的用途
|
EP1893632B1
(en)
|
2005-06-17 |
2015-08-12 |
Novo Nordisk Health Care AG |
Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
|
US7695710B2
(en)
|
2005-06-20 |
2010-04-13 |
Pepgen Corporation |
Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
|
KR20080037656A
(ko)
*
|
2005-06-20 |
2008-04-30 |
펩젠 코포레이션 |
저독성의 장시간 순환하는 사람 인터페론-알파 유사체 및인터페론 타우의 키메라
|
EA014157B1
(ru)
*
|
2005-06-29 |
2010-10-29 |
Йеда Рисерч Энд Дивелопмент Ко. Лтд. |
РЕКОМБИНАНТНЫЕ МУТАНТЫ ИНТЕРФЕРОНА α2 (IFNα2)
|
EP2305697A3
(en)
|
2005-07-25 |
2011-07-27 |
Intermune, Inc. |
Macrocyclic inhibitors of Hepatitis C virus replication
|
US7632823B2
(en)
*
|
2005-08-18 |
2009-12-15 |
Ambrx, Inc. |
Compositions of tRNA and uses thereof
|
PT1931697E
(pt)
|
2005-09-28 |
2010-12-06 |
Zymogenetics Inc |
Antagonistas de il-17a e il-17f e processos para a sua utilização
|
US8119592B2
(en)
|
2005-10-11 |
2012-02-21 |
Intermune, Inc. |
Compounds and methods for inhibiting hepatitis C viral replication
|
CN101291684A
(zh)
*
|
2005-10-21 |
2008-10-22 |
阿维季尼克斯股份有限公司 |
甘醇化和糖基化的禽类来源的治疗性蛋白
|
US20080171696A1
(en)
*
|
2005-10-21 |
2008-07-17 |
Avigenics, Inc. |
Pharmacodynamically enhanced therapeutic proteins
|
JP5508716B2
(ja)
*
|
2005-11-08 |
2014-06-04 |
アンブルックス,インコーポレイテッド |
非天然アミノ酸、および非天然アミノ酸ポリペプチドを修飾するための促進剤
|
KR20080079643A
(ko)
*
|
2005-11-16 |
2008-09-01 |
암브룩스, 인코포레이티드 |
비-천연 아미노산을 포함하는 방법 및 조성물
|
EP1968635B1
(en)
*
|
2005-12-14 |
2014-09-17 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
AU2007205545B9
(en)
|
2006-01-12 |
2012-10-18 |
Hokusan Co. Ltd. |
Oral composition containing interferon-alpha
|
CN100475270C
(zh)
|
2006-01-20 |
2009-04-08 |
清华大学 |
一种治疗肿瘤的药物及其应用
|
CN101002945B
(zh)
|
2006-01-20 |
2012-09-05 |
清华大学 |
一种用于肿瘤治疗的新型复合物
|
JP5167244B2
(ja)
|
2006-04-11 |
2013-03-21 |
ノバルティス アーゲー |
Hcv/hiv阻害剤およびそれらの使用
|
US20080096819A1
(en)
*
|
2006-05-02 |
2008-04-24 |
Allozyne, Inc. |
Amino acid substituted molecules
|
US7632492B2
(en)
*
|
2006-05-02 |
2009-12-15 |
Allozyne, Inc. |
Modified human interferon-β polypeptides
|
US20090252720A1
(en)
|
2006-05-24 |
2009-10-08 |
Novo Nordisk Health Care Ag |
Prolonged FIX Analogues and Derivatives
|
US7985734B2
(en)
|
2006-06-01 |
2011-07-26 |
Yun Cheng |
Peptides for preventing or treating liver damage
|
CN1911447B
(zh)
*
|
2006-06-30 |
2010-05-12 |
复旦大学 |
转铁蛋白-聚乙二醇-药物分子复合物及其制备药物的用途
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
CA2666814A1
(en)
*
|
2006-08-21 |
2008-05-29 |
United Therapeutics Corporation |
Combination therapy for treatment of viral infections
|
CA2662753C
(en)
*
|
2006-09-08 |
2016-02-23 |
Ambrx, Inc. |
Hybrid suppressor trna for vertebrate cells
|
WO2008030614A2
(en)
*
|
2006-09-08 |
2008-03-13 |
Ambrx, Inc. |
Suppressor trna transcription in vertebrate cells
|
MX2009002523A
(es)
*
|
2006-09-08 |
2009-03-20 |
Ambrx Inc |
Polipeptido de plasma humano modificado o andamios fc y sus usos.
|
BRPI0719597A2
(pt)
|
2006-11-22 |
2013-12-17 |
Adnexus A Bristol Myers Squibb R & D Company |
Produtos terapêuticos objetivados baseados em proteínas manipuladas para receptores de quinases de tirosina, incluindo igf-ir
|
CN101219219B
(zh)
|
2007-01-10 |
2013-02-13 |
北京普罗吉生物科技发展有限公司 |
包含血管抑素或其片段的复合物、其制备方法及应用
|
EP2111228B1
(en)
|
2007-02-02 |
2011-07-20 |
Bristol-Myers Squibb Company |
10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis
|
ATE554785T1
(de)
|
2007-03-30 |
2012-05-15 |
Ambrx Inc |
Modifizierte fgf-21 polypeptide und ihre verwendung
|
AU2008247815B2
(en)
*
|
2007-05-02 |
2012-09-06 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
CA2707840A1
(en)
|
2007-08-20 |
2009-02-26 |
Allozyne, Inc. |
Amino acid substituted molecules
|
ES2386575T3
(es)
*
|
2007-09-04 |
2012-08-23 |
Biosteed Gene Expression Tech. Co., Ltd. |
Interferón alfa 2a modificado por polietilenglicol, su proceso de síntesis y su aplicación
|
ATE548382T1
(de)
*
|
2007-09-04 |
2012-03-15 |
Biosteed Gene Expression Tech Co Ltd |
Polyethylenglykolmodifiziertes interferon alpha 2b und herstellungsverfahren und anwendungen davon
|
EP2197489B2
(en)
|
2007-10-04 |
2020-04-01 |
ZymoGenetics, Inc. |
B7 family member zb7h6 and related compositions and methods
|
US8216571B2
(en)
|
2007-10-22 |
2012-07-10 |
Schering Corporation |
Fully human anti-VEGF antibodies and methods of using
|
KR101656107B1
(ko)
|
2007-11-20 |
2016-09-08 |
암브룩스, 인코포레이티드 |
변형된 인슐린 폴리펩티드 및 이의 용도
|
PT2796466T
(pt)
|
2007-12-07 |
2018-02-23 |
Zymogenetics Inc |
Moléculas de anticorpo humanizado específicas para il-31
|
MX344166B
(es)
|
2008-02-08 |
2016-12-07 |
Ambrx Inc |
Leptina-polipeptidos modificados y sus usos.
|
BRPI0822530B1
(pt)
|
2008-04-03 |
2022-03-22 |
Biosteed Gene Expression Tech. Co., Ltd |
Método de preparação de um hormônio de crescimento humano glicolado por polietileno (modificado por peg), hormônio do crescimento humano modificado por peg de menor peso molecular aparente e seu uso, preparação de hormônio do crescimento humano modificado por peg de menor peso molecular aparente e seu método de preparação e composição
|
JP2011520961A
(ja)
|
2008-05-22 |
2011-07-21 |
ブリストル−マイヤーズ スクイブ カンパニー |
多価フィブロネクチンをベースとする足場ドメインタンパク質
|
EP2313105B1
(en)
|
2008-06-27 |
2013-07-24 |
ZymoGenetics, Inc. |
SOLUBLE HYBRID Fc gamma RECEPTORS AND RELATED METHODS
|
NZ600382A
(en)
*
|
2008-07-23 |
2013-11-29 |
Ambrx Inc |
Modified bovine G-CSF polypeptides and their uses
|
NZ607477A
(en)
|
2008-09-26 |
2014-09-26 |
Ambrx Inc |
Non-natural amino acid replication-dependent microorganisms and vaccines
|
EP3216800A1
(en)
|
2008-09-26 |
2017-09-13 |
Ambrx, Inc. |
Modified animal erythropoietin polypeptides and their uses
|
WO2010039801A2
(en)
|
2008-10-02 |
2010-04-08 |
The J. David Gladstone Institutes |
Methods of treating hepatitis c virus infection
|
WO2010107739A2
(en)
|
2009-03-18 |
2010-09-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions of treating a flaviviridae family viral infection
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
MX2011012665A
(es)
|
2009-06-04 |
2012-03-07 |
Novartis Ag |
Metodos para identificacion de sitios para conjugacion de igg.
|
WO2011014882A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
|
KR20120106942A
(ko)
|
2009-10-30 |
2012-09-27 |
베링거 인겔하임 인터내셔날 게엠베하 |
Bi201335, 인터페론 알파 및 리바비린을 포함하는 hcv 병용 치료요법을 위한 투여 용법
|
US20120283172A1
(en)
|
2009-12-21 |
2012-11-08 |
Ambrx, Inc. |
Modified porcine somatotropin polypeptides and their uses
|
CN107674121A
(zh)
|
2009-12-21 |
2018-02-09 |
Ambrx 公司 |
经过修饰的牛促生长素多肽和其用途
|
US20120135912A1
(en)
|
2010-05-10 |
2012-05-31 |
Perseid Therapeutics Llc |
Polypeptide inhibitors of vla4
|
US9394294B2
(en)
|
2010-05-11 |
2016-07-19 |
Demerx, Inc. |
Methods and compositions for preparing and purifying noribogaine
|
US8765737B1
(en)
|
2010-05-11 |
2014-07-01 |
Demerx, Inc. |
Methods and compositions for preparing and purifying noribogaine
|
US8362007B1
(en)
|
2010-05-11 |
2013-01-29 |
Demerx, Inc. |
Substituted noribogaine
|
EP3091028A1
(en)
|
2010-05-26 |
2016-11-09 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins having improved stability
|
US20120123338A1
(en)
|
2010-06-16 |
2012-05-17 |
Medtronic, Inc. |
Damping systems for stabilizing medications in drug delivery devices
|
US9586954B2
(en)
|
2010-06-22 |
2017-03-07 |
Demerx, Inc. |
N-substituted noribogaine prodrugs
|
US8741891B1
(en)
|
2010-06-22 |
2014-06-03 |
Demerx, Inc. |
N-substituted noribogaine prodrugs
|
US8637648B1
(en)
|
2010-06-22 |
2014-01-28 |
Demerx, Inc. |
Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
|
US8802832B2
(en)
|
2010-06-22 |
2014-08-12 |
Demerx, Inc. |
Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
|
CA2803093A1
(en)
|
2010-06-24 |
2011-12-29 |
Panmed Ltd. |
Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
|
UA111065C2
(uk)
|
2010-07-23 |
2016-03-25 |
Демеркс, Інк. |
Композиції норибогаїну
|
WO2012024452A2
(en)
|
2010-08-17 |
2012-02-23 |
Ambrx, Inc. |
Modified relaxin polypeptides and their uses
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
AR083337A1
(es)
|
2010-10-05 |
2013-02-21 |
Novartis Ag |
Tratamientos de infeccion por el virus de hepatitis c
|
EP2624826B1
(en)
|
2010-10-08 |
2018-07-18 |
Novartis AG |
Vitamin e formulations of sulfamide ns3 inhibitors
|
US20130251678A1
(en)
|
2010-11-30 |
2013-09-26 |
Novartis Ag |
Bid dosage regimen for deb025
|
EP2481740B1
(en)
|
2011-01-26 |
2015-11-04 |
DemeRx, Inc. |
Methods and compositions for preparing noribogaine from voacangine
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
CN105749246A
(zh)
|
2011-03-31 |
2016-07-13 |
诺华股份有限公司 |
治疗丙肝病毒感染的阿拉泊韦
|
EP2694087B1
(en)
|
2011-04-01 |
2015-01-28 |
Novartis AG |
Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases
|
WO2012140082A1
(en)
|
2011-04-13 |
2012-10-18 |
Novartis Ag |
Treatment of hepatitis c virus infection with alisporivir
|
EP2709669A1
(en)
|
2011-05-17 |
2014-03-26 |
Bristol-Myers Squibb Company |
Methods for maintaining pegylation of polypeptides
|
WO2012158493A2
(en)
|
2011-05-19 |
2012-11-22 |
Geysen Hendrik M |
Compounds that bind to the erythropoietin receptor
|
AR087020A1
(es)
|
2011-07-01 |
2014-02-05 |
Bayer Ip Gmbh |
Polipeptidos de fusion de relaxina y usos de los mismos
|
WO2013011113A1
(en)
|
2011-07-20 |
2013-01-24 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for determining treatment response in patients infected with hcv genotype 4
|
WO2013028233A1
(en)
*
|
2011-08-25 |
2013-02-28 |
Nanogen Pharmaceutical Biotechnology |
Peg-interferon lambda 1 conjugates
|
US9617274B1
(en)
|
2011-08-26 |
2017-04-11 |
Demerx, Inc. |
Synthetic noribogaine
|
MX2014003753A
(es)
|
2011-09-27 |
2014-05-01 |
Novartis Ag |
Alisporivir para el tratamiento de la infeccion por virus de la hepatitis c.
|
EP2773659A2
(en)
|
2011-10-31 |
2014-09-10 |
Bristol-Myers Squibb Company |
Fibronectin binding domains with reduced immunogenicity
|
US9364484B2
(en)
|
2011-12-06 |
2016-06-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for treating viral diseases
|
EP2788003A4
(en)
|
2011-12-09 |
2015-05-27 |
Demerx Inc |
PHOSPHATESTER OF NORIBOGAIN
|
EP2807168A4
(en)
|
2012-01-25 |
2015-10-14 |
Demerx Inc |
SYNTHETIC VOACANGINE
|
US9150584B2
(en)
|
2012-01-25 |
2015-10-06 |
Demerx, Inc. |
Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
|
US8454947B1
(en)
|
2012-03-01 |
2013-06-04 |
Nanogen Pharmaceutical Biotechnology |
PEG-interferon lambda 1 conjugates
|
WO2013137869A1
(en)
|
2012-03-14 |
2013-09-19 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
|
WO2013143581A1
(en)
|
2012-03-28 |
2013-10-03 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in specific patient subgenotype sub-population
|
CN104411332B
(zh)
|
2012-03-30 |
2018-11-23 |
索伦托治疗有限公司 |
与vegfr2结合的全人抗体
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
WO2013174988A1
(en)
|
2012-05-24 |
2013-11-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting and monitoring treatment response in hcv- and hcv/hiv-infected subjects
|
CN115093480A
(zh)
|
2012-05-31 |
2022-09-23 |
索伦托药业有限公司 |
与pd-l1结合的抗原结合蛋白
|
SI2859017T1
(sl)
|
2012-06-08 |
2019-05-31 |
Sutro Biopharma, Inc. |
Protitelesa, ki vsebujejo specifične nenaravne aminokislinske ostanke, postopki njihove priprave in postopki njihove uporabe
|
EP2863946A4
(en)
|
2012-06-21 |
2016-04-13 |
Sorrento Therapeutics Inc |
ANTIGEN-BINDING PROTEINS THAT BIND TO C-MET
|
EP2864358B1
(en)
|
2012-06-22 |
2019-08-07 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind ccr2
|
EP3135690A1
(en)
|
2012-06-26 |
2017-03-01 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
PL3584255T3
(pl)
|
2012-08-31 |
2022-05-16 |
Sutro Biopharma, Inc. |
Modyfikowane aminokwasy zawierające grupę azydkową
|
US20140205566A1
(en)
|
2012-11-30 |
2014-07-24 |
Novartis Ag |
Cyclic nucleuoside derivatives and uses thereof
|
US8940728B2
(en)
|
2012-12-20 |
2015-01-27 |
Demerx, Inc. |
Substituted noribogaine
|
US9783535B2
(en)
|
2012-12-20 |
2017-10-10 |
Demerx, Inc. |
Substituted noribogaine
|
US9045481B2
(en)
|
2012-12-20 |
2015-06-02 |
Demerx, Inc. |
Substituted noribogaine
|
US20150361159A1
(en)
|
2013-02-01 |
2015-12-17 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins
|
WO2014194302A2
(en)
|
2013-05-31 |
2014-12-04 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-1
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
EP3137078B1
(en)
|
2014-05-01 |
2019-03-20 |
Eiger Biopharmaceuticals, Inc. |
Treatment of hepatitis delta virus infection
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
US11311519B2
(en)
|
2014-05-01 |
2022-04-26 |
Eiger Biopharmaceuticals, Inc. |
Treatment of hepatitis delta virus infection
|
US10076512B2
(en)
|
2014-05-01 |
2018-09-18 |
Eiger Biopharmaceuticals, Inc. |
Treatment of hepatitis delta virus infection
|
WO2015195673A2
(en)
|
2014-06-18 |
2015-12-23 |
Demerx, Inc. |
Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
|
WO2016025645A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
EP3180018B1
(en)
|
2014-08-12 |
2019-07-24 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
SG11201701382PA
(en)
|
2014-08-22 |
2017-03-30 |
Sorrento Therapeutics Inc |
Antigen binding proteins that bind cxcr3
|
US9987241B2
(en)
|
2014-09-25 |
2018-06-05 |
The Board Of Regents Of The University Of Oklahoma |
Enzyme conjugate and prodrug cancer therapy
|
SI3412302T1
(sl)
|
2014-10-24 |
2021-09-30 |
Bristol-Myers Squibb Company |
Modificirani FGF-21 polipeptidi in njihova uporaba
|
EP3215193B1
(en)
*
|
2014-11-06 |
2023-10-04 |
PharmaEssentia Corporation |
Dosage regimen for pegylated interferon
|
EP3272857B1
(en)
*
|
2015-03-17 |
2020-08-12 |
Shigetaka Shimodaira |
Method for preparing dendritic cell by non-adhesive culture using ifn
|
DK3285768T3
(da)
|
2015-04-21 |
2021-01-25 |
Eiger Biopharmaceuticals Inc |
Farmaceutiske sammensætninger omfattende lonafarnib og ritonavir
|
CN108135979A
(zh)
|
2015-11-03 |
2018-06-08 |
豪夫迈·罗氏有限公司 |
Hbv衣壳组装抑制剂和干扰素的组合疗法
|
JP7187315B2
(ja)
|
2015-11-04 |
2022-12-12 |
アイガー・バイオファーマシューティカルズ・インコーポレイテッド |
デルタ型肝炎ウイルス感染の処置
|
EA037855B1
(ru)
|
2016-01-29 |
2021-05-27 |
Сорренто Терапьютикс, Инк. |
Полностью человеческое антитело класса igg, связывающееся с эпитопом pd-l1
|
WO2018087345A1
(en)
|
2016-11-14 |
2018-05-17 |
F. Hoffmann-La Roche Ag |
COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
CA3049656A1
(en)
|
2017-01-10 |
2018-07-19 |
Nodus Therapeutics |
Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
|
JP7189399B2
(ja)
|
2017-01-18 |
2022-12-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
骨髄増殖性障害を患う患者の処置のための方法及び医薬組成物
|
AU2018219283B2
(en)
|
2017-02-08 |
2022-05-19 |
Bristol-Myers Squibb Company |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
EP3658173A1
(en)
|
2017-07-25 |
2020-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating monocytopoiesis
|
WO2020032951A1
(en)
|
2018-08-09 |
2020-02-13 |
The Board Of Regents Of The University Of Oklahoma |
Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
|
US11485781B2
(en)
|
2017-08-17 |
2022-11-01 |
Massachusetts Institute Of Technology |
Multiple specificity binders of CXC chemokines
|
WO2020056066A1
(en)
|
2018-09-11 |
2020-03-19 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and their uses
|
BR112021004383A2
(pt)
|
2018-09-28 |
2021-08-03 |
Massachusetts Institute Of Technology |
proteína de fusão imunomoduladora, composição farmacêutica, ácido nucleico, vetor de expressão, célula transformada, método para a produção de uma proteína de fusão imunomoduladora, método para ativar, aumentar ou promover uma resposta por uma célula imune em um sujeito, método para inibir, reduzir ou suprimir uma resposta por uma célula imune em um sujeito, método para reduzir ou inibir o crescimento do tumor, método para tratar câncer em um sujeito, kit, uso de uma proteína de fusão imunomoduladora e método para reduzir ou inibir o crescimento do tumor ou tratar o câncer em um sujeito
|
CN113366015A
(zh)
|
2018-10-19 |
2021-09-07 |
Ambrx公司 |
白细胞介素-10多肽缀合物、其二聚体及其用途
|
WO2020154032A1
(en)
|
2019-01-23 |
2020-07-30 |
Massachusetts Institute Of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
CN113660957A
(zh)
|
2019-02-12 |
2021-11-16 |
Ambrx公司 |
包含抗体-tlr激动剂缀合物的组合物、方法和用途
|
MX2022000742A
(es)
|
2019-07-18 |
2022-02-14 |
Enyo Pharma |
Metodo para disminuir los efectos adversos del interferon.
|
US20210285000A1
(en)
|
2020-03-05 |
2021-09-16 |
Janssen Pharmaceuticals, Inc. |
Combination therapy for treating hepatitis b virus infection
|
AU2021233909A1
(en)
|
2020-03-11 |
2022-09-29 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
WO2021228983A1
(en)
|
2020-05-13 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
|
ES2929379T3
(es)
|
2020-05-20 |
2022-11-28 |
Inst Nat Sante Rech Med |
Métodos para el tratamiento de infecciones por coronavirus
|
CA3185614A1
(en)
|
2020-06-22 |
2021-12-30 |
Janssen Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis d virus infection
|
KR20230073200A
(ko)
|
2020-08-20 |
2023-05-25 |
암브룩스, 인코포레이티드 |
항체-tlr 작용제 접합체, 그 방법 및 용도
|
WO2022043496A2
(en)
|
2020-08-28 |
2022-03-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of mait cells as biomarkers and biotargets in covid-19
|
WO2022079205A1
(en)
|
2020-10-15 |
2022-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of ifn-alpha polypeptides for the treatment of coronavirus infections
|
WO2022159414A1
(en)
|
2021-01-22 |
2022-07-28 |
University Of Rochester |
Erythropoietin for gastroinfestinal dysfunction
|
JP2024512775A
(ja)
|
2021-04-03 |
2024-03-19 |
アンブルックス,インコーポレイテッド |
抗her2抗体薬物コンジュゲート及びその使用
|